Vanguard Group Inc. Raises Stake in Catalent, Inc. (NYSE:CTLT)

Vanguard Group Inc. grew its stake in Catalent, Inc. (NYSE:CTLT - Free Report) by 1.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 20,468,027 shares of the company's stock after buying an additional 365,648 shares during the quarter. Vanguard Group Inc. owned 11.33% of Catalent worth $931,909,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of CTLT. Capital World Investors increased its stake in Catalent by 19.1% during the 2nd quarter. Capital World Investors now owns 15,960,335 shares of the company's stock worth $692,040,000 after buying an additional 2,556,699 shares in the last quarter. BlackRock Inc. grew its position in shares of Catalent by 4.2% in the second quarter. BlackRock Inc. now owns 14,918,877 shares of the company's stock valued at $646,883,000 after purchasing an additional 603,729 shares in the last quarter. State Street Corp grew its position in shares of Catalent by 4.7% in the second quarter. State Street Corp now owns 7,535,900 shares of the company's stock valued at $326,757,000 after purchasing an additional 337,297 shares in the last quarter. Cadian Capital Management LP grew its position in shares of Catalent by 91.0% in the third quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company's stock valued at $241,527,000 after purchasing an additional 2,526,750 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Catalent by 41.7% in the third quarter. Barclays PLC now owns 4,797,718 shares of the company's stock valued at $218,440,000 after purchasing an additional 1,412,058 shares in the last quarter.

Analysts Set New Price Targets

CTLT has been the subject of several analyst reports. StockNews.com initiated coverage on Catalent in a research report on Monday. They issued a "sell" rating for the company. Royal Bank of Canada reiterated a "sector perform" rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Stephens reiterated an "equal weight" rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 6th. UBS Group reiterated a "neutral" rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Finally, Barclays upped their price target on Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a research note on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $52.46.

Catalent Stock Down 0.1 %

NYSE:CTLT traded down $0.03 during trading hours on Thursday, hitting $55.85. The company's stock had a trading volume of 2,024,325 shares, compared to its average volume of 2,937,616. The stock has a market capitalization of $10.09 billion, a P/E ratio of -8.22, a price-to-earnings-growth ratio of 3.54 and a beta of 1.20. The stock has a fifty day moving average of $55.01 and a 200-day moving average of $46.90. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. Catalent, Inc. has a 52-week low of $31.45 and a 52-week high of $68.81.

Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The business had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business's quarterly revenue was down 10.2% compared to the same quarter last year. During the same period last year, the company earned $0.62 EPS. On average, equities analysts forecast that Catalent, Inc. will post 0.48 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.